These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36698055)

  • 1. Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US.
    Elkind MSV; Witte KK; Kasner SE; Sawyer LM; Grimsey Jones FW; Rinciog C; Tsintzos S; Rosemas SC; Lanctin D; Ziegler PD; Reynolds MR
    BMC Cardiovasc Disord; 2023 Jan; 23(1):45. PubMed ID: 36698055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the UK.
    Rinciog CI; Sawyer LM; Diamantopoulos A; Elkind MSV; Reynolds M; Tsintzos SI; Ziegler PD; Quiroz ME; Wolff C; Witte KK
    Open Heart; 2019; 6(1):e001037. PubMed ID: 31297227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke.
    Diamantopoulos A; Sawyer LM; Lip GY; Witte KK; Reynolds MR; Fauchier L; Thijs V; Brown B; Quiroz Angulo ME; Diener HC
    Int J Stroke; 2016 Apr; 11(3):302-12. PubMed ID: 26763916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of insertable cardiac monitors for the detection of atrial fibrillation in patients with cryptogenic stroke in the United States is cost-effective.
    Maervoet J; Bossers N; Borge RP; Hilpert ST; van Engen A; Smala A
    J Med Econ; 2019 Nov; 22(11):1221-1234. PubMed ID: 31480905
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke.
    Sawyer LM; Witte KK; Reynolds MR; Mittal S; Grimsey Jones FW; Rosemas SC; Ziegler PD; Kaplon RE; Yaghi S
    J Comp Eff Res; 2021 Feb; 10(2):127-141. PubMed ID: 33300381
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
    Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
    Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of the use of non-vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: a modelling analysis using the healthcare system in the Netherlands.
    Bennaghmouch N; de Veer AJWM; Mahmoodi BK; Jofre-Bonet M; Lip GYH; Bode K; Ten Berg JM
    Eur Heart J Qual Care Clin Outcomes; 2019 Apr; 5(2):127-135. PubMed ID: 30016398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
    Ruiz Vargas E; Sposato LA; Lee SAW; Hachinski V; Cipriano LE
    Stroke; 2018 Dec; 49(12):2844-2850. PubMed ID: 30571418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
    Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.
    Kleintjens J; Li X; Simoens S; Thijs V; Goethals M; Rietzschel ER; Asukai Y; Saka Ö; Evers T; Faes P; Vansieleghem S; De Ruyck M
    Pharmacoeconomics; 2013 Oct; 31(10):909-18. PubMed ID: 24030788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.
    Athanasakis K; Karampli E; Tsounis D; Bilitou A; Kyriopoulos J
    Clin Drug Investig; 2015 Nov; 35(11):693-705. PubMed ID: 26385756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of insertable cardiac monitors for diagnosis of atrial fibrillation in cryptogenic stroke in Australia.
    Thijs V; Witte KK; Guarnieri C; Makino K; Tilden D; Gillespie J; Huynh M
    J Arrhythm; 2021 Aug; 37(4):1077-1085. PubMed ID: 34386135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
    Rudakova AV; Tatarskiĭ BA
    Kardiologiia; 2014; 54(7):43-52. PubMed ID: 25177813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China.
    Dong SJ; Wu B; Zhai SD; Zhang YJ; Chu YB; Gupta P; Li YH
    Clin Ther; 2020 Jan; 42(1):144-156.e1. PubMed ID: 31932080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
    Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
    Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
    Hernandez I; Smith KJ; Zhang Y
    Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
    Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
    Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.
    Shah A; Shewale A; Hayes CJ; Martin BC
    Stroke; 2016 Jun; 47(6):1555-61. PubMed ID: 27103018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.